Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. Svensson

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP

European HIV Clinical Forum 2016

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

European HIV Clinical Forum 2016

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

European HIV Clinical Forum 2016

Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD

European HIV Clinical Forum 2016

Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé

European HIV Clinical Forum 2016

French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez

European HIV Clinical Forum 2016

An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli

European HIV Clinical Forum 2016

Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath

European HIV Clinical Forum 2016

Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD

European HIV Clinical Forum 2016

Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps

European HIV Clinical Forum 2016

Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti

European HIV Clinical Forum 2016

Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting

European HIV Clinical Forum 2016

Induction-Maintenance ARV Therapy: Why, Who, When and How? - Pedro Cahn, MD, PhD

European HIV Clinical Forum 2016

Clinical Case Presentations - Experience with Induction-Maintenance Therapy in real life settings - José Arribas, MD

European HIV Clinical Forum 2016

Maintenance Therapy with Dolutegravir/Rilpivirin is efficient and well tolerated in a real-life setting - Katharina Grabmeijer Pfistershammer

European HIV Clinical Forum 2016

How to manage drug - drug interactions - the theory - Giovanni Di Perri, MD, PhD

European HIV Clinical Forum 2016

Study of early development of broadly neutralizing antibodies in HIV-1-infected infants - Cassandra Simonich, MD/PhD Candidate

International Workshop on HIV Transmission 2016

The fine specificity and autologous virus neutralization potency of maternal antibodies that predict reduced HIV-1 mother to child transmission - Sallie Permar, MD, PhD

International Workshop on HIV Transmission 2016

Studies in early acute infection and implications for transmission and cure - Merlin Robb, MD

International Workshop on HIV Transmission 2016

The Role of TAF in PrEP - Katy Garrett, PharmD

International Workshop on HIV Transmission 2016

Research update: drug development - Myron Cohen, MD

International Workshop on HIV Transmission 2016

Local situation in Turkey | Serhat Unal, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Russia | Vadim Rassokhin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016